Clinical Trial Update: [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) [Phase 2]

View source ↗

Summary

Phase 2 imaging trial evaluating [68Ga]-NeoBOMB1 for GRPR-expressing tumors has terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• 68Ga-NeoBOMB1 (68Ga-NeoBOMB1)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Breast Cancer, Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-10-23